Exelixis Company Profile (NASDAQ:EXEL)

About Exelixis (NASDAQ:EXEL)

Exelixis logoExelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ capsules are approved for progressive, metastatic medullary thyroid cancer. The third product, Cotellic, is a formulation of cobimetinib, a selective inhibitor of MEK is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a range of forms of cancer and are the subjects of broad clinical development programs. The Company's XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:EXEL
  • CUSIP: 30161Q10
  • Web: www.exelixis.com
Capitalization:
  • Market Cap: $5.9 billion
  • Outstanding Shares: 292,512,000
Average Prices:
  • 50 Day Moving Avg: $21.27
  • 200 Day Moving Avg: $19.44
  • 52 Week Range: $6.16 - $24.85
P/E:
  • Trailing P/E Ratio: 960.48
  • Foreward P/E Ratio: 38.79
  • P/E Growth: 2.54
Sales & Book Value:
  • Annual Revenue: $256.91 million
  • Price / Sales: 22.97
  • Book Value: $0.41 per share
  • Price / Book: 49.20
Profitability:
  • EBIDTA: $43.6 million
  • Net Margins: -123.81%
  • Return on Assets: -30.16%
Debt:
  • Debt-to-Equity Ratio: 2.54%
  • Current Ratio: 2.09%
  • Quick Ratio: 2.07%
Misc:
  • Average Volume: 3.88 million shs.
  • Beta: 1.78
  • Short Ratio: 4.06
 

Frequently Asked Questions for Exelixis (NASDAQ:EXEL)

What is Exelixis' stock symbol?

Exelixis trades on the NASDAQ under the ticker symbol "EXEL."

How were Exelixis' earnings last quarter?

Exelixis, Inc. (NASDAQ:EXEL) posted its quarterly earnings results on Monday, May, 1st. The company reported $0.05 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.01) by $0.06. The company had revenue of $80.90 million for the quarter, compared to analyst estimates of $65.23 million. The firm's revenue for the quarter was up 425.3% compared to the same quarter last year. During the same period last year, the firm earned ($0.27) EPS. View Exelixis' Earnings History.

When will Exelixis make its next earnings announcement?

Exelixis is scheduled to release their next quarterly earnings announcement on Tuesday, August, 1st 2017. View Earnings Estimates for Exelixis.

Where is Exelixis' stock going? Where will Exelixis' stock price be in 2017?

10 brokerages have issued 12 month price targets for Exelixis' shares. Their predictions range from $8.00 to $28.00. On average, they expect Exelixis' share price to reach $17.60 in the next twelve months. View Analyst Ratings for Exelixis.

What are analysts saying about Exelixis stock?

Here are some recent quotes from research analysts about Exelixis stock:

  • 1. According to Zacks Investment Research, "Exelixis posted an earnings in the first quarter compared to a loss in the year-ago quarter which was encouraging. The sequential increase in Cabometyx sales is a positive for the company. Exelixis received a major boost with the FDA approval of Cabometyx tablets in Apr 2016. Initial uptake of the drug was encouraging and is expected to propel the top line in the forthcoming quarters. Moreover, Cabometyx also received approval in the EU in September, which triggered a milestone payment of $60 million to Exelixis. Moreover, Exelixis is developing cabozantinib in a broad development program and plans to file a supplemental New Drug Application (sNDA) in the third quarter of 2017 for advanced RCC. Moreover, successful commercialization of the other marketed drug, Cotellic in the U.S. will boost the top line. Exelixis’ share price outperformed the Zacks classified Biomedical and Genetics industry year to date." (5/3/2017)
  • 2. Cann analysts commented, "Based on indications that Cabometyx is being adopted more quickly in Q1 2017 than we had anticipated, we are adjusting our expected market penetration ramp." (4/19/2017)

Who are some of Exelixis' key competitors?

Who owns Exelixis stock?

Exelixis' stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (14.66%), Vanguard Group Inc. (8.11%), Meditor Group Ltd (6.60%), BlackRock Inc. (6.55%), State Street Corp (2.64%) and Goldman Sachs Group Inc. (2.13%). Company insiders that own Exelixis stock include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi. View Institutional Ownership Trends for Exelixis.

Who sold Exelixis stock? Who is selling Exelixis stock?

Exelixis' stock was sold by a variety of institutional investors in the last quarter, including Meditor Group Ltd, Acadian Asset Management LLC, Morgan Stanley, Janus Capital Management LLC, Goldman Sachs Group Inc., Emerald Advisers Inc. PA, Emerald Mutual Fund Advisers Trust and Wellington Management Group LLP. Company insiders that have sold Exelixis stock in the last year include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jack L Wyszomierski, Jeffrey Hessekiel, Michael Morrissey, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi. View Insider Buying and Selling for Exelixis.

Who bought Exelixis stock? Who is buying Exelixis stock?

Exelixis' stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Old Mutual Global Investors UK Ltd., Vanguard Group Inc., Wells Fargo & Company MN, OppenheimerFunds Inc., MARSHALL WACE ASIA Ltd, Marshall Wace North America L.P. and Gotham Asset Management LLC. View Insider Buying and Selling for Exelixis.

How do I buy Exelixis stock?

Shares of Exelixis can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Exelixis stock cost?

One share of Exelixis stock can currently be purchased for approximately $20.17.

Analyst Ratings

Consensus Ratings for Exelixis (NASDAQ:EXEL) (?)
Ratings Breakdown: 4 Hold Ratings, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: $17.60 (12.77% downside)

Analysts' Ratings History for Exelixis (NASDAQ:EXEL)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/4/2017Oppenheimer Holdings Inc.Reiterated RatingMarket PerformMediumView Rating Details
4/19/2017CannReiterated RatingHoldLowView Rating Details
3/31/2017Needham & Company LLCInitiated CoverageBuy -> Buy$28.00MediumView Rating Details
3/16/2017CIBCInitiated CoverageMarket Perform -> Market PerformHighView Rating Details
3/1/2017William BlairReiterated RatingOutperformN/AView Rating Details
2/28/2017Stifel NicolausDowngradeBuy -> Hold$22.00N/AView Rating Details
1/24/2017Cowen and CompanyReiterated RatingOutperformN/AView Rating Details
11/3/2016Deutsche Bank AGInitiated CoverageBuy$17.00N/AView Rating Details
10/10/2016Piper Jaffray CompaniesUpgradeNeutral -> OverweightN/AView Rating Details
10/7/2016Leerink SwannReiterated RatingPositive$15.00N/AView Rating Details
9/28/2016S&P Equity ResearchBoost Price Target$13.41 -> $15.57N/AView Rating Details
(Data available from 5/25/2015 forward)

Earnings

Earnings History for Exelixis (NASDAQ:EXEL)
Earnings by Quarter for Exelixis (NASDAQ:EXEL)
Earnings History by Quarter for Exelixis (NASDAQ:EXEL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/1/2017        
5/1/2017Q1 2017($0.01)$0.05$65.23 million$80.90 millionViewListenView Earnings Details
2/27/2017Q416($0.01)$0.12$64.88 million$77.58 millionViewListenView Earnings Details
11/3/2016Q316($0.13)($0.04)$43.15 million$62.19 millionViewN/AView Earnings Details
8/3/2016Q216($0.27)($0.16)$16.76 million$36.25 millionViewListenView Earnings Details
5/4/2016Q116($0.25)($0.27)$9.11 million$15.40 millionViewListenView Earnings Details
2/29/2016Q415($0.22)($0.19)$8.16 million$9.94 millionViewListenView Earnings Details
11/10/2015Q315($0.20)($0.22)$9.08 million$9.85 millionViewListenView Earnings Details
8/11/2015Q215($0.21)($0.22)$8.69 million$8.00 millionViewListenView Earnings Details
4/30/2015Q115($0.24)($0.18)$8.08 million$9.40 millionViewListenView Earnings Details
2/24/2015Q414($0.31)($0.30)$7.50 million$7.35 millionViewListenView Earnings Details
11/4/2014Q314($0.37)($0.32)$6.77 million$6.30 millionViewListenView Earnings Details
7/31/2014Q214($0.39)($0.38)$5.66 million$6.56 millionViewListenView Earnings Details
5/1/2014Q114($0.37)($0.39)$6.11 million$4.90 millionViewListenView Earnings Details
2/20/2014Q413($0.38)($0.38)$5.71 million$4.34 millionViewListenView Earnings Details
10/30/2013Q313($0.37)($0.36)$5.55 million$5.50 millionViewListenView Earnings Details
8/6/2013Q2 2013($0.30)($0.34)$6.55 million$11.90 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.29)($0.24)$5.33 million$9.70 millionViewListenView Earnings Details
2/21/2013Q4 2012($0.24)($0.28)$9.46 million$7.80 millionViewListenView Earnings Details
11/7/2012Q312($0.30)($0.20)$9.22 million$13.30 millionViewN/AView Earnings Details
8/2/2012($0.27)($0.25)ViewN/AView Earnings Details
5/3/2012($0.19)($0.18)ViewN/AView Earnings Details
10/27/2011$0.57$0.60ViewN/AView Earnings Details
8/4/2011($0.17)($0.16)ViewN/AView Earnings Details
5/3/2011($0.19)($0.24)ViewN/AView Earnings Details
2/22/2011($0.21)($0.16)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Exelixis (NASDAQ:EXEL)
2017 EPS Consensus Estimate: $0.04
2018 EPS Consensus Estimate: $0.32
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.03)$0.01($0.01)
Q2 20173$0.01$0.03$0.02
Q3 20173$0.00$0.03$0.01
Q4 20173$0.00$0.04$0.02
Q1 20181$0.06$0.06$0.06
Q2 20181$0.07$0.07$0.07
Q3 20181$0.09$0.09$0.09
Q4 20181$0.10$0.10$0.10
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Exelixis (NASDAQ:EXEL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Exelixis (NASDAQ:EXEL)
Insider Ownership Percentage: 5.90%
Institutional Ownership Percentage: 78.40%
Insider Trades by Quarter for Exelixis (NASDAQ:EXEL)
Institutional Ownership by Quarter for Exelixis (NASDAQ:EXEL)
Insider Trades by Quarter for Exelixis (NASDAQ:EXEL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/15/2017Carl B FeldbaumDirectorSell32,988$21.58$711,881.04View SEC Filing  
5/10/2017Michael MorrisseyInsiderSell211,300$21.87$4,621,131.00View SEC Filing  
5/9/2017Michael MorrisseyCEOSell100,000$21.69$2,169,000.00View SEC Filing  
5/8/2017Michael MorrisseyCEOSell11,300$21.81$246,453.00View SEC Filing  
5/5/2017Michael MorrisseyInsiderSell259,149$22.24$5,763,473.76View SEC Filing  
5/1/2017Gisela SchwabCMOSell89,910$23.01$2,068,829.10View SEC Filing  
4/3/2017Vincent T MarchesiDirectorSell10,000$21.30$213,000.00View SEC Filing  
3/31/2017Jack L WyszomierskiDirectorSell5,150$21.57$111,085.50View SEC Filing  
3/27/2017Jeffrey HessekielEVPSell6,884$21.02$144,701.68View SEC Filing  
3/22/2017Jeffrey HessekielEVPSell23,787$20.54$488,584.98View SEC Filing  
3/20/2017Stelios PapadopoulosDirectorSell10,000$21.66$216,600.00View SEC Filing  
3/13/2017Charles CohenDirectorSell10,000$21.82$218,200.00View SEC Filing  
3/10/2017Vincent T MarchesiDirectorSell40,000$21.98$879,200.00View SEC Filing  
3/6/2017Michael MorrisseyInsiderSell200,000$22.72$4,544,000.00View SEC Filing  
3/3/2017Christopher J. SennerCFOSell11,000$22.80$250,800.00View SEC Filing  
3/2/2017George PosteDirectorSell76,250$22.53$1,717,912.50View SEC Filing  
1/3/2017Peter LambEVPSell70,000$14.65$1,025,500.00View SEC Filing  
12/16/2016Carl B. FeldbaumDirectorSell25,000$17.03$425,750.00View SEC Filing  
12/9/2016Alan M. GarberDirectorSell7,832$16.90$132,360.80View SEC Filing  
12/7/2016George A. ScangosDirectorSell204,894$17.81$3,649,162.14View SEC Filing  
12/5/2016George A. ScangosDirectorSell204,718$17.81$3,646,027.58View SEC Filing  
12/1/2016Gisela SchwabInsiderSell22,000$16.73$368,060.00View SEC Filing  
12/1/2016Peter LambEVPSell70,000$16.66$1,166,200.00View SEC Filing  
8/4/2016Gisela SchwabInsiderSell42,338$11.00$465,718.00View SEC Filing  
5/11/2016Lance WillseyDirectorBuy60,000$4.97$298,200.00View SEC Filing  
5/9/2016Lance WillseyDirectorBuy40,000$4.97$198,800.00View SEC Filing  
12/11/2015Lance WillseyDirectorBuy100,000$4.89$489,000.00View SEC Filing  
10/16/2015Peter LambEVPSell51,549$5.80$298,984.20View SEC Filing  
10/13/2015Peter LambEVPSell600$5.80$3,480.00View SEC Filing  
10/12/2015Peter LambEVPSell300,276$5.84$1,753,611.84View SEC Filing  
9/17/2014Vincent T MarchesiDirectorBuy20,000$1.71$34,200.00View SEC Filing  
8/29/2013Lance WillseyDirectorBuy10,000$5.15$51,500.00View SEC Filing  
12/20/2012Vincent T MarchesiDirectorBuy4,000$4.68$18,720.00View SEC Filing  
12/19/2012Vincent T MarchesiDirectorBuy6,000$4.72$28,320.00View SEC Filing  
12/10/2012Gisela SchwabEVPBuy25,000$4.39$109,750.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Exelixis (NASDAQ:EXEL)
Latest Headlines for Exelixis (NASDAQ:EXEL)
Source:
DateHeadline
seekingalpha.com logoExelixis Could Still Be A Buy - Seeking Alpha
seekingalpha.com - May 24 at 4:53 PM
streetinsider.com logoForm 4 EXELIXIS, INC. For: May 15 Filed by: FELDBAUM CARL B - StreetInsider.com
www.streetinsider.com - May 17 at 5:05 PM
streetinsider.com logoForm 4 EXELIXIS, INC. For: May 15 Filed by: FELDBAUM CARL B
www.streetinsider.com - May 17 at 10:39 AM
americanbankingnews.com logoExelixis, Inc. (EXEL) Director Sells $711,881.04 in Stock
www.americanbankingnews.com - May 16 at 10:16 PM
americanbankingnews.com logoExelixis, Inc. (EXEL) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 16 at 8:44 AM
americanbankingnews.com logo Analysts Expect Exelixis, Inc. (EXEL) to Announce $0.03 Earnings Per Share
www.americanbankingnews.com - May 16 at 12:22 AM
finance.yahoo.com logoETFs with exposure to Exelixis, Inc. : May 15, 2017
finance.yahoo.com - May 15 at 4:48 PM
americanbankingnews.com logoExelixis, Inc. (EXEL) CEO Michael Morrissey Sells 11,300 Shares
www.americanbankingnews.com - May 10 at 11:26 PM
americanbankingnews.com logoMichael Morrissey Sells 100,000 Shares of Exelixis, Inc. (EXEL) Stock
www.americanbankingnews.com - May 10 at 10:24 PM
americanbankingnews.com logoExelixis, Inc. (EXEL) Insider Michael Morrissey Sells 211,300 Shares
www.americanbankingnews.com - May 10 at 10:23 PM
streetinsider.com logoForm 4 EXELIXIS, INC. For: May 08 Filed by: MORRISSEY MICHAEL
www.streetinsider.com - May 10 at 10:14 PM
finance.yahoo.com logoExelixis, Inc. breached its 50 day moving average in a Bearish Manner : EXEL-US : May 9, 2017
finance.yahoo.com - May 9 at 9:12 AM
americanbankingnews.com logoExelixis, Inc. (EXEL) Upgraded at TheStreet
www.americanbankingnews.com - May 6 at 11:14 PM
americanbankingnews.com logoExelixis, Inc. (EXEL) Insider Sells $5,763,473.76 in Stock
www.americanbankingnews.com - May 5 at 7:54 PM
americanbankingnews.com logoExelixis, Inc. (EXEL) Stock Rating Reaffirmed by Oppenheimer Holdings Inc.
www.americanbankingnews.com - May 5 at 12:46 AM
americanbankingnews.com logoExelixis (EXEL) Given Daily Media Sentiment Rating of -0.02
www.americanbankingnews.com - May 4 at 7:24 PM
finance.yahoo.com logoETFs with exposure to Exelixis, Inc. : May 4, 2017
finance.yahoo.com - May 4 at 5:14 PM
americanbankingnews.com logoExelixis, Inc. Forecasted to Post FY2017 Earnings of $0.11 Per Share (EXEL)
www.americanbankingnews.com - May 4 at 3:38 PM
americanbankingnews.com logoLeerink Swann Weighs in on Exelixis, Inc.'s Q2 2017 Earnings (EXEL)
www.americanbankingnews.com - May 4 at 8:10 AM
americanbankingnews.com logoGisela Schwab Sells 89,910 Shares of Exelixis, Inc. (EXEL) Stock
www.americanbankingnews.com - May 4 at 1:03 AM
investopedia.com logoWill Exelixis Break Out from Key Resistance? (EXEL)
www.investopedia.com - May 3 at 9:58 PM
finance.yahoo.com logoExelixis, Inc. :EXEL-US: Earnings Analysis: Q1, 2017 By the Numbers : May 3, 2017
finance.yahoo.com - May 3 at 9:58 PM
finance.yahoo.com logoWill Exelixis Break Out from Key Resistance?
finance.yahoo.com - May 3 at 9:58 PM
businesswire.com logoExelixis Announces First Quarter 2017 Financial Results and ... - Business Wire (press release)
www.businesswire.com - May 3 at 4:56 PM
finance.yahoo.com logoExelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Yahoo Finance
finance.yahoo.com - May 3 at 4:56 PM
fool.com logo5 Things Exelixis Inc. Management Said After the Q1 Earnings Blowout That You'll Want to Know - Motley Fool
www.fool.com - May 3 at 4:56 PM
americanbankingnews.com logoQ4 2017 EPS Estimates for Exelixis, Inc. Cut by Leerink Swann (EXEL)
www.americanbankingnews.com - May 3 at 3:24 PM
americanbankingnews.com logoWilliam Blair Weighs in on Exelixis, Inc.'s Q3 2017 Earnings (EXEL)
www.americanbankingnews.com - May 3 at 10:58 AM
americanbankingnews.com logoOppenheimer Holdings Weighs in on Exelixis, Inc.'s Q3 2017 Earnings (EXEL)
www.americanbankingnews.com - May 3 at 10:58 AM
finance.yahoo.com logoBlog Coverage Sunesis Pharma Withdraws European Marketing Authorization Application for Vosaroxin
finance.yahoo.com - May 3 at 8:24 AM
seekingalpha.com logoExelixis, Inc. 2017 Q1 - Results - Earnings Call Slides
seekingalpha.com - May 2 at 7:48 PM
bizjournals.com logoInvestors: Covered Call reports for Exelixis, Facebook, Priceline, Pfizer Inc. and AT&T include trade ideas that offer returns of 18% or more!
www.bizjournals.com - May 2 at 7:48 PM
finance.yahoo.com logoEdited Transcript of EXEL earnings conference call or presentation 1-May-17 9:00pm GMT
finance.yahoo.com - May 2 at 7:48 PM
finance.yahoo.com logoThis Biotech Is Flirting With A Breakout After 'Another Strong Quarter'
finance.yahoo.com - May 2 at 7:48 PM
fool.com logoWhoa, an Operating Profit for Exelixis, Inc.
www.fool.com - May 2 at 3:52 PM
americanbankingnews.com logoExelixis, Inc. (EXEL) Releases Quarterly Earnings Results, Beats Estimates By $0.06 EPS
www.americanbankingnews.com - May 2 at 1:18 PM
fool.com logo5 Things Exelixis Inc. Management Said After the Q1 Earnings Blowout That You'll Want to Know
www.fool.com - May 2 at 12:55 PM
americanbankingnews.com logoExelixis (EXEL) Given News Impact Rating of 0.09
www.americanbankingnews.com - May 1 at 6:32 PM
nasdaq.com logoInteresting EXEL Put And Call Options For June 16th
www.nasdaq.com - May 1 at 4:56 PM
finance.yahoo.com logoInvestor Network: Exelixis, Inc. to Host Earnings Call
finance.yahoo.com - May 1 at 4:56 PM
finance.yahoo.com logoExelixis Announces First Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - May 1 at 4:56 PM
finance.yahoo.com logoExelixis beats Street 1Q forecasts
finance.yahoo.com - May 1 at 4:56 PM
americanbankingnews.com logoExelixis, Inc. (EXEL) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - April 29 at 7:08 AM
americanbankingnews.com logoExelixis (EXEL) Given News Sentiment Score of 0.38
www.americanbankingnews.com - April 28 at 2:04 PM
finance.yahoo.com logoExelixis, Inc. – Value Analysis (NASDAQ:EXEL) : April 27, 2017
finance.yahoo.com - April 27 at 5:39 PM
americanbankingnews.com logo$65.59 Million in Sales Expected for Exelixis, Inc. (EXEL) This Quarter
www.americanbankingnews.com - April 27 at 12:52 PM
finance.yahoo.com logoBehind Exelixis’s Successful Commercial Launch of Cabometyx in 2016
finance.yahoo.com - April 27 at 11:19 AM
finance.yahoo.com logoExelixis’s Tough Competition in Renal Cell Carcinoma
finance.yahoo.com - April 27 at 11:19 AM
finance.yahoo.com logoInside Exelixis’s Robust Growth Strategy for Cabometyx
finance.yahoo.com - April 27 at 11:19 AM
finance.yahoo.com logoExelixis, Inc. breached its 50 day moving average in a Bullish Manner : EXEL-US : April 26, 2017
finance.yahoo.com - April 26 at 10:34 PM

Social

Chart

Exelixis (EXEL) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by MarketBeat.com Staff